Drug profile · INN
asenapine maleate
ASENAPINE MALEATE
asenapine maleate (ASENAPINE MALEATE) is a dopamine d2 receptor antagonist. Route of administration: sublingual. Current US regulatory status: approved.
Drug details — asenapine maleate
- US status
- approved
- Class
- —
- Route
- SUBLINGUAL
- Patents
- 3
- Programs
- 5
- Data quality
- 0.84
Quick answer
asenapine maleate (ASENAPINE MALEATE) is a dopamine d2 receptor antagonist. Route of administration: sublingual. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025146482
FINÉRÉNONE DESTINÉE À ÊTRE UTILISÉE DANS UN PROCÉDÉ DE PRÉVENTION OU DE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE CHEZ UN PATIENT RECEVANT UN INHIBITEUR DE CYP3A4 OU UN INDUCTEUR DE CYP3A4
granted -
EP 4567715
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted -
EP 4567716
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted
Frequently asked questions
What is asenapine maleate?
asenapine maleate (ASENAPINE MALEATE) is a dopamine d2 receptor antagonist. Route of administration: sublingual. Current US regulatory status: approved.
What is the brand name for asenapine maleate?
ASENAPINE MALEATE is a marketed brand name for asenapine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of asenapine maleate?
asenapine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.